Hepatitis B surface antigen prevalence and the rates of mother-to-child transmission of hepatitis B virus after the introduction of infant vaccination programs in South East Asia and Western Pacific regions: a systematic review.

Autor:	Marjenberg Z; Maverex Limited, Newcastle upon Tyne, United Kingdom. Electronic address: ZoeMarjenberg@maverex.com., Wright C; Maverex Limited, Newcastle upon Tyne, United Kingdom. Electronic address: CiaraWright@maverex.com., Pooley N; Maverex Limited, Newcastle upon Tyne, United Kingdom. Electronic address: NickPooley@maverex.com., Cheung KW; Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China. Electronic address: kelvincheung82@hotmail.com., Shimakawa Y; Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France. Electronic address: yusuke.shimakawa@gmail.com., Vargas-Zambrano JC; Sanofi, 14 espace Henry Vallée, 69007 Lyon, France. Electronic address: Juan.Vargas@sanofi.com., Vidor E; Sanofi, 14 espace Henry Vallée, 69007 Lyon, France. Electronic address: Emmanuel.Vidor@sanofi.com.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2022 Nov; Vol. 124, pp. 65-75. Date of Electronic Publication: 2022 Sep 09.
DOI:	10.1016/j.ijid.2022.09.003
Abstrakt:	Objectives: Infant vaccination against the hepatitis B virus began in the World Health Organization South East Asia Region and the Western Pacific Region between 1983 and 2016. This systematic review examined the seroprevalence of hepatitis B surface antigen (HBsAg) in children and the rate of mother-to-child transmission (MTCT) in these regions between 1990 and 2020. Methods: MEDLINE and EMBASE were searched for articles published between January 1990 and September 2020, which reported seroprevalence of HBsAg in children aged 0-15 years and/or the rate of MTCT in the South East Asia Region and Western Pacific Region. A pragmatic review identified supporting information. This review was registered in the International Prospective Register of Systematic Reviews (#CRD42020211707). Results: Of 115 included studies, 77 (24 countries) reported HBsAg prevalence, and 38 (nine countries) reported MTCT. The seroprevalence of HBsAg ranged between 0.0% and 27.4%, with a decreasing trend over time in each country. MTCT rates were 0.0-5.2% in infants of mothers who are hepatitis B e antigen-negative and 2.7-53.0% in infants of mothers who are hepatitis B e antigen-positive. Conclusion: After the introduction of infant hepatitis B virus vaccination programs, the countries in South East Asia Region and Western Pacific Region observed a reduction in HBsAg seroprevalence in children. Nevertheless, the risk of MTCT persists, emphasizing the importance of antenatal screening to identify high-risk pregnancies. Competing Interests: Declaration of competing interests KC declares no competing interests. YS received research grants from Gilead Sciences. ZM, NP, and CW received consulting fees from Sanofi. JCVZ and EV are Sanofi employees, a manufacturer, and distributor of many hepatitis B-containing combination vaccines and may hold shares and/or stock options in the company. (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu